8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 14, 2015

Cardiovascular Systems, Inc.

(Exact name of Registrant as Specified in its Charter)

Delaware	000-52082	41-1698056
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1225 Old Highway 8 Northwest

St. Paul, Minnesota 55112-6416

(Address of Principal Executive Offices and Zip Code)

(651) 259-1600

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On September 14, 2015, Cardiovascular Systems, Inc. (the “Company”) issued a press release regarding the medical condition of its President and Chief Executive Officer, David Martin. On the same day, Mr. Martin issued a message to the Company’s employees informing them of his condition. A copy of the press release is attached to this Report as Exhibit 99.1 and a copy of Mr. Martin’s message is attached to this Report as Exhibit 99.2.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Press release of Cardiovascular Systems, Inc., dated September 14, 2015.
99.2	Message from David Martin.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 14, 2015

CARDIOVASCULAR SYSTEMS, INC.
By:	/s/ Laurence L. Betterley
	Laurence L. Betterley Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release of Cardiovascular Systems, Inc., dated September 14, 2015.
99.2	Message from David Martin.

EX-99.1

Exhibit 99.1

CARDIOVASCULAR SYSTEMS DISCLOSES HEALTH CONDITION OF CEO, DAVE MARTIN

Martin Will Continue to Lead Company During Cancer Treatment

St. Paul, Minn. - Sept. 14, 2015 - Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) said today that its President and CEO, David Martin, has recently been diagnosed with cancer and is undergoing treatment. Martin is feeling well and will continue to perform his duties as CEO, though some activities, such as travel, may be limited.

Scott Ward, Chairman of CSI’s Board, said, “Dave is an outstanding leader and has the full support of the Board. We wish him a rapid recovery. While he will continue to serve as CEO, Dave has also developed a talented management team that we are confident can lead the company as needed during his treatment and recovery.”

Earlier today, Martin sent a letter to CSI employees sharing his diagnosis. A copy of that letter can be found here: http://investors.csi360.com/Investors/Investor-Resources/Letter.

About Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in peripheral arteries in August 2007. In October 2013, the company received FDA approval for the use of the Diamondback Orbital Atherectomy System in coronary arteries. To date, nearly 210,000 of CSI’s devices have been sold to leading institutions across the United States. For more information, visit the company’s website at www.csi360.com

Contacts:

Cardiovascular Systems, Inc. Jack Nielsen (651) 202-4919 jnielsen@csi360.com PadillaCRT Matt Sullivan (612) 455-1709 matt.sullivan@padillacrt.com

EX-99.2

Exhibit 99.2

September 14, 2015

To my CSI Family, our ONE CSI,

I was recently diagnosed with stomach cancer. The cancer is stage two and my doctors believe that it’s curable. I have faith in God and am blessed with unbelievable love and support from my family and friends, including my CSI family. For that, I am very happy and appreciative.

My treatment plan is in place and I have begun chemotherapy, with surgery expected later this year. I plan to actively lead our business during my treatment, though some activities, such as travel, will be limited.

Our CSI mission is clear - to provide vascular relief throughout the body to millions in need and in doing so dramatically reduce the number of amputations performed every year. We have the pieces necessary to accomplish this goal in the U.S. and beyond, as we expand internationally.

We are committed to patients in need and their families. Our medical education programs support our health care provider friends and heroes. We deliver confidence to insurance payors and to patients by providing clear proof of clinical and economic outcome benefits. Our technology provides unique, safe, and effective products for vascular intervention. Finally, CSI has outstanding talent and leadership. I’m proud of this special organization and what we’ve achieved. I am even more excited about the contributions we will make for many years to come.

I will fight my disease with our trademark CSI heart and intensity and will keep you updated on my progress. Thank you for the inspiring work that you do every day—I’m honored to be working with such an amazing team—ONE CSI.

Dave

Exhibit 99.2